Tohoku J. Exp. Med., 2024 February, 262(2)

Bivalirudin versus Heparin on Net Adverse Clinical Events, Major Adverse Cardiac and Cerebral Events, and Bleeding in Elderly Chinese Patients Treated with Percutaneous Coronary Intervention

Qin Li,¹ Huayun Li,¹ Zhongfei Liu¹ and Lingxiao Duan²

¹Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China
²Department of Critical Care Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China

Bivalirudin as an anticoagulant reduces bleeding after percutaneous coronary intervention (PCI), while its impact in elderly Chinese patients treated with PCI needs more evidence. This study aimed to compare the clinical outcomes between bivalirudin and heparin in elderly Chinese patients treated with PCI. This cohort study retrieved data of 1,286 elderly patients treated with PCI who used bivalirudin (bivalirudin group, N = 493) or heparin (heparin group, N = 793) as anticoagulants. Net adverse clinical events (NACEs) (primary endpoint), major adverse cardiac and cerebral events (MACCEs), bleeding, and major bleeding within 30 days after PCI treatment were recorded for analysis. Our study illustrated that NACEs (12.4% vs. 17.4%, P = 0.009], bleeding (OR: 0.499, P = 0.003) in these patients. In summary, bivalirudin achieves fewer NACEs, bleeding, and major bleeding, but not MACCEs, versus heparin in elderly patients treated with PCI, which is verified in the multivariate model.

Key words —— bivalirudin; bleeding; heparin; major adverse cardiac and cerebral events; percutaneous coronary intervention

© 2024 Tohoku University Medical Press

===============================

Tohoku J. Exp. Med., 2024 February, 262(2), 115-124.

Correspondence: Lingxiao Duan, Department of Critical Care Medicine, The Affiliated Hospital, Southwest Medical University, No. 25, Taiping Road, Luzhou, Sichuan 646000, China.

e-mail: duan93744693@163.com